This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the Topline Results from the Phase 2b CORAL Trial of of Trevi Therapeutics' Haduvio (oral nalbuphine ER) in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Ticker(s): TRVI

Who's the expert?

Institution: St. Agnes Hospital/Ascension

  • Pulmonologist and Critical Care Physician at St. Agnes Hospital (Baltimore)
  • Manage patients with NTM lung disease (and the sequela of NTM) and PAP.
  • Board certified Pulmonary and Critical Care; leadership role in Society of Critical Care Medicine Maryland Chapter and via THRIVE Task Force (national).  

Interview Goal
Examining the Topline Results from the Phase 2b CORAL Trial of of Trevi Therapeutics' Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.